pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.’s NICE for ILUVIEN® for DME

[Business Wire] – WATERTOWN, Mass.–(BUSINESSWIRE)– pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that … more

View todays social media effects on PSDV

View the latest stocks trending across Twitter. Click to view dashboard